688428 诺诚健华
已收盘 07-16 15:00:01
资讯
新帖
简况
诺诚健华-索法西替尼二期试验展现良好安全性，未出现新的安全信号
美股速递 · 07-16 21:11
诺诚健华-索法西替尼二期试验展现良好安全性，未出现新的安全信号
诺诚健华旗下Soficitinib在II期试验中较安慰剂展现统计学显著改善
美股速递 · 07-16 21:04
诺诚健华旗下Soficitinib在II期试验中较安慰剂展现统计学显著改善
诺诚健华TYK2抑制剂索法西替尼治疗白癜风II期研究达主要终点
美股速递 · 07-16 21:01
诺诚健华TYK2抑制剂索法西替尼治疗白癜风II期研究达主要终点
诺诚健华(688428.SH)：Soficitinib(ICP-332)治疗非节段型白癜风Ⅱ期研究达到主要终点
智通财经 · 07-16 16:42
诺诚健华(688428.SH)：Soficitinib(ICP-332)治疗非节段型白癜风Ⅱ期研究达到主要终点
诺诚健华（688428）披露2023年人民币股份激励计划归属结果，7月15日股价下跌2.18%
证券之星 · 07-15 22:07
诺诚健华（688428）披露2023年人民币股份激励计划归属结果，7月15日股价下跌2.18%
诺诚健华-奥布替尼达到统计学显著主要终点及多个次要终点
美股速递 · 07-15 19:55
诺诚健华-奥布替尼达到统计学显著主要终点及多个次要终点
诺诚健华宣布TYK2抑制剂Soficitinib治疗特应性皮炎III期研究达到主要终点
美股速递 · 07-15 19:55
诺诚健华宣布TYK2抑制剂Soficitinib治疗特应性皮炎III期研究达到主要终点
诺诚健华(09969)：soficitinib (ICP-332)治疗中重度特应性皮炎的 III期注册性试验成功达到其主要终点
智通财经 · 07-15 18:58
诺诚健华(09969)：soficitinib (ICP-332)治疗中重度特应性皮炎的 III期注册性试验成功达到其主要终点
诺诚健华：Soficitinib治疗中重度特应性皮炎Ⅲ期临床试验达主要终点
格隆汇 · 07-15 18:50
诺诚健华：Soficitinib治疗中重度特应性皮炎Ⅲ期临床试验达主要终点
每周股票复盘：诺诚健华（688428）科创板股份归属上市
证券之星 · 07-12
每周股票复盘：诺诚健华（688428）科创板股份归属上市
诺诚健华（688428）披露2023年科创板限制性股票激励计划归属结果暨股份上市公告，7月10日股价上涨2.34%
证券之星 · 07-10
诺诚健华（688428）披露2023年科创板限制性股票激励计划归属结果暨股份上市公告，7月10日股价上涨2.34%
港股创新药概念股盘中拉升，荣昌生物、诺诚健华涨超5%
老虎资讯综合 · 07-10
港股创新药概念股盘中拉升，荣昌生物、诺诚健华涨超5%
诺诚健华：截止到2026年6月30日公司A股股东户数约为2万户
证券之星 · 07-07
诺诚健华：截止到2026年6月30日公司A股股东户数约为2万户
诺诚健华盘中涨超9% 自研靶向CDH17的新型ADC创新药ICP-B208完成首例患者给药
新浪港股 · 07-06
诺诚健华盘中涨超9% 自研靶向CDH17的新型ADC创新药ICP-B208完成首例患者给药
诺诚健华宣布新型Cdh17靶向ADC药物ICP-B208中国临床试验首例患者完成给药
美股速递 · 07-06
诺诚健华宣布新型Cdh17靶向ADC药物ICP-B208中国临床试验首例患者完成给药
诺诚健华（688428）披露根据2023年股权激励计划授出受限制股份单位，7月1日股价上涨3.86%
证券之星 · 07-01
诺诚健华（688428）披露根据2023年股权激励计划授出受限制股份单位，7月1日股价上涨3.86%
半导体设备板块短线走低，恒运昌跌超13%
智通财经 · 07-01
半导体设备板块短线走低，恒运昌跌超13%
6月29日诺诚健华涨13.08%，富国精准医疗混合A基金重仓该股
证券之星 · 06-29
6月29日诺诚健华涨13.08%，富国精准医疗混合A基金重仓该股
诺诚健华涨13.08%，长城国瑞证券二个月前给出“买入”评级
证券之星 · 06-29
诺诚健华涨13.08%，长城国瑞证券二个月前给出“买入”评级
诺诚健华(09969)：根据2024年人民币股股份激励计划发行241.83万股新人民币股份
智通财经 · 06-26
诺诚健华(09969)：根据2024年人民币股股份激励计划发行241.83万股新人民币股份
暂无数据
公司概况
公司名称：
诺诚健华医药有限公司
所属行业：
医药制造业
上市日期：
2022-09-21
主营业务：
诺诚健华医药有限公司的主营业务是创新药的研发、生产及商业化。公司的主要产品是奥布替尼。
发行价格：
11.03
{"stockData":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"诺诚健华","latestPrice":29.21,"timestamp":1784185201000,"preClose":29.63,"halted":0,"volume":16405105,"delay":0,"changeRate":-0.0142,"floatShares":273000000,"shares":1769000000,"eps":0.4129,"marketStatus":"已收盘","change":-0.42,"latestTime":"07-16 15:00:01","open":29.8,"high":30.9,"low":29,"amount":491000000,"amplitude":0.0641,"askPrice":29.21,"askSize":26,"bidPrice":29.2,"bidSize":6,"shortable":0,"etf":0,"ttmEps":0.4129,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784251800000},"marketStatusCode":5,"adr":0,"adjPreClose":29.63,"symbolType":"stock_kcb","openAndCloseTimeList":[[1784165400000,1784172600000],[1784178000000,1784185200000]],"highLimit":32.59,"lowLimit":26.67,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1769107002,"isCdr":false,"pbRate":7.04,"roa":"--","peRate":70.743521,"roe":"1.4%","epsLYR":0.38,"committee":-0.140794,"marketValue":51676000000,"turnoverRate":0.0601,"status":1,"afterMarket":{"amount":90551,"volume":3100,"close":29.21,"buyVolume":0,"sellVolume":2195,"time":1784187237746,"indexStatus":"已收盘 07-16 15:30:00","preClose":29.63},"hkstockBrief":{"symbol":"09969","market":"HK","secType":"STK","nameCN":"诺诚健华","latestPrice":14.69,"timestamp":1784189314009,"preClose":14.8,"halted":0,"volume":11764871,"delay":0,"premium":"-56.54"},"floatMarketCap":7969000000},"requestUrl":"/m/hq/s/688428/tweets","defaultTab":"tweets","newsList":[{"id":"1122082851","title":"诺诚健华-索法西替尼二期试验展现良好安全性，未出现新的安全信号","url":"https://stock-news.laohu8.com/highlight/detail?id=1122082851","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122082851?lang=zh_cn&edition=full","pubTime":"2026-07-16 21:11","pubTimestamp":1784207485,"startTime":"0","endTime":"0","summary":"诺诚健华旗下的候选药物索法西替尼，在二期临床试验中展现出良好的安全性特征，研究过程中未观察到新的安全信号。这一积极数据为这款在研药物的后续开发提供了重要支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128065417","title":"诺诚健华旗下Soficitinib在II期试验中较安慰剂展现统计学显著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1128065417","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128065417?lang=zh_cn&edition=full","pubTime":"2026-07-16 21:04","pubTimestamp":1784207075,"startTime":"0","endTime":"0","summary":"诺诚健华（Innocare Pharma）宣布，其在研药物Soficitinib于一项II期临床试验中，与安慰剂相比，取得了统计学上显著的改善效果。该结果标志着该候选药物的研发取得了积极进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688428","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129132601","title":"诺诚健华TYK2抑制剂索法西替尼治疗白癜风II期研究达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1129132601","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129132601?lang=zh_cn&edition=full","pubTime":"2026-07-16 21:01","pubTimestamp":1784206873,"startTime":"0","endTime":"0","summary":"诺诚健华宣布，其TYK2抑制剂索法西替尼在针对白癜风患者的II期临床研究中，达到了预设的主要终点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651417153","title":"诺诚健华(688428.SH)：Soficitinib(ICP-332)治疗非节段型白癜风Ⅱ期研究达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2651417153","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651417153?lang=zh_cn&edition=full","pubTime":"2026-07-16 16:42","pubTimestamp":1784191344,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华 发布公告，公司自主研发的新一代高选择性口服酪氨酸激酶2抑制剂soficitinib用于治疗非节段型白癜风患者的II/III期适应性临床研究中，II期阶段成功达到主要终点，并取得积极顶线结果。Soficitinib是公司自主研发的新一代高选择性口服TYK2抑制剂。TYK2属于Janus激酶家族成员，在白细胞介素-12/IL-23家族细胞因子受体及I型干扰素受体下游信号传导过程中发挥重要作用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1468424.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","688428","09969","BK0239","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651469258","title":"诺诚健华（688428）披露2023年人民币股份激励计划归属结果，7月15日股价下跌2.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651469258","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651469258?lang=zh_cn&edition=full","pubTime":"2026-07-15 22:07","pubTimestamp":1784124436,"startTime":"0","endTime":"0","summary":"截至2026年7月15日收盘，诺诚健华报收于29.63元，较前一交易日下跌2.18%，最新总市值为524.19亿元。该股当日开盘30.31元，最高31.9元，最低29.12元，成交额达7.09亿元，换手率为8.46%。近日，诺诚健华医药有限公司根据2023年人民币股份激励计划的归属结果，向2名董事、1名高级管理人员及132名激励对象发行新人民币股份，合计1,644,750股，每股发行价为人民币6.95元。本次发行后，公司已发行股份总数由2026年6月30日的1,764,576,252股增至1,766,221,002股。此次变动未导致库存股份变动。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500044610.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","688428","BK0239","BK1574","09969","UCmain","MCNHmain","MUCmain","CNHmain","CYB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124883174","title":"诺诚健华-奥布替尼达到统计学显著主要终点及多个次要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1124883174","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124883174?lang=zh_cn&edition=full","pubTime":"2026-07-15 19:55","pubTimestamp":1784116513,"startTime":"0","endTime":"0","summary":"诺诚健华宣布，其创新药物奥布替尼在临床试验中成功达到预设的统计学显著主要终点，并同时达成了多个关键的次要终点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140913795","title":"诺诚健华宣布TYK2抑制剂Soficitinib治疗特应性皮炎III期研究达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1140913795","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140913795?lang=zh_cn&edition=full","pubTime":"2026-07-15 19:55","pubTimestamp":1784116512,"startTime":"0","endTime":"0","summary":"诺诚健华公布其TYK2抑制剂Soficitinib用于治疗特应性皮炎的III期临床研究结果，该研究成功达到了预设的主要终点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651452404","title":"诺诚健华(09969)：soficitinib (ICP-332)治疗中重度特应性皮炎的 III期注册性试验成功达到其主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2651452404","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651452404?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:58","pubTimestamp":1784113097,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华 公布，公司自主研发的新一代口服酪氨酸激酶2抑制剂soficitinib ，用于治疗中重度特应性皮炎患者的III期注册性临床试验成功达到其主要终点。研究结果显示，soficitinib 达到主要终点，在统计学上具有显著性，并取得具有临床意义的改善。公司将继续完成正在进行中的III期研究，包括长期安全性随访，并计划于研究完成后推进soficitinib 用于治疗中重度特应性皮炎的注册申报工作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467988.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK0239","09969","III","688428","BK1161","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651452187","title":"诺诚健华：Soficitinib治疗中重度特应性皮炎Ⅲ期临床试验达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2651452187","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651452187?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:50","pubTimestamp":1784112604,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["688428","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650815490","title":"每周股票复盘：诺诚健华（688428）科创板股份归属上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2650815490","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650815490?lang=zh_cn&edition=full","pubTime":"2026-07-12 02:32","pubTimestamp":1783794729,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，诺诚健华报收于29.78元，较上周的30.18元下跌1.33%。本周关注点来自公司公告汇总：诺诚健华完成2023年科创板限制性股票激励计划部分归属，新增股份2,044,750股于2026年7月15日上市。诺诚健华医药有限公司完成2023年科创板限制性股票激励计划首次授予部分第三个归属期及预留授予部分第二个归属期的股份登记工作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071200000813.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","688428","BK0239","BK1574","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650010135","title":"诺诚健华（688428）披露2023年科创板限制性股票激励计划归属结果暨股份上市公告，7月10日股价上涨2.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650010135","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650010135?lang=zh_cn&edition=full","pubTime":"2026-07-10 22:29","pubTimestamp":1783693755,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，诺诚健华报收于29.78元，较前一交易日上涨2.34%，最新总市值为526.23亿元。公告显示，公司已完成2023年科创板限制性股票激励计划首次授予部分第三个归属期及预留授予部分第二个归属期的股份登记工作。本次归属合计134人，归属股票数量为2,044,750股，来源为公司向激励对象定向发行人民币普通股股票。上市流通日为2026年7月15日。安永华明会计师事务所已完成验资，公司已收到激励对象缴纳的合计人民币14,211,012.50元出资款。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000044628.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1161","BK0239","09969","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180945737","title":"港股创新药概念股盘中拉升，荣昌生物、诺诚健华涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1180945737","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180945737?lang=zh_cn&edition=full","pubTime":"2026-07-10 10:01","pubTimestamp":1783648919,"startTime":"0","endTime":"0","summary":"7月10日，港股创新药概念股盘中拉升，$荣昌生物(09995)$、$诺诚健华(09969)$涨超5%，$药明康德(02359)$、$药明生物(02269)$、$亚盛医药(06855)$、$乐普生物(02157)$涨超4%，$恒瑞医药(01276)$涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/a5d11890cd6ccd454a56d86737fd3353","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/a5d11890cd6ccd454a56d86737fd3353"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","BK1574","BK0239","IBBQ","VXUS","BK1583","BK1161","688428","KCAI","159992","LU1064130708.USD","09969","BK4588","BK4585","LU1064131003.USD","688331","LU1969619763.USD","LU2148510915.USD","LU2328871848.SGD","LU2488822045.USD","MEDX","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649985891","title":"诺诚健华：截止到2026年6月30日公司A股股东户数约为2万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2649985891","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649985891?lang=zh_cn&edition=full","pubTime":"2026-07-07 17:06","pubTimestamp":1783415169,"startTime":"0","endTime":"0","summary":"证券之星消息，诺诚健华(688428)07月07日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司截止6月30日的股东人数诺诚健华回复：尊敬的投资者，您好！截止到2026年6月30日公司A股股东户数约为2万户。感谢您的关注！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070700028459.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688428","BK0239","BK1161","BK1574","159982","09969","399300"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649461757","title":"诺诚健华盘中涨超9% 自研靶向CDH17的新型ADC创新药ICP-B208完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2649461757","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649461757?lang=zh_cn&edition=full","pubTime":"2026-07-06 09:52","pubTimestamp":1783302720,"startTime":"0","endTime":"0","summary":" 诺诚健华盘中涨超9%，截至发稿，股价上涨6.42%，现报13.92港元，成交额5426.90万港元。 7月6日，据诺诚健华官微消息，公司宣布自主研发的靶向CDH17的新型ADC创新药ICP-B208完成首例患者给药。基于诺诚健华自主研发的ADC技术平台，ICP-208由人源化抗CDH17抗体通过蛋白酶可裂解连接子与公司自主开发的强效有效载荷偶联而成，可精准靶向肿瘤细胞，同时最大限度减少脱靶效应。目前，全球尚无CDH17靶向ADC新药上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-07-06/doc-inifvqsf1795989.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09969","BK0239","MEDX","06978","BK4231","BK1161","159992","BK4080","688428","IBBQ","NETL","ADC","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140314939","title":"诺诚健华宣布新型Cdh17靶向ADC药物ICP-B208中国临床试验首例患者完成给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1140314939","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140314939?lang=zh_cn&edition=full","pubTime":"2026-07-06 09:01","pubTimestamp":1783299689,"startTime":"0","endTime":"0","summary":"诺诚健华宣布，其新型Cdh17靶向抗体偶联药物ICP-B208在中国的临床试验中，已完成对首例患者的给药。这一进展标志着该创新疗法在中国正式进入临床研究阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648549090","title":"诺诚健华（688428）披露根据2023年股权激励计划授出受限制股份单位，7月1日股价上涨3.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648549090","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648549090?lang=zh_cn&edition=full","pubTime":"2026-07-01 22:23","pubTimestamp":1782915793,"startTime":"0","endTime":"0","summary":"截至2026年7月1日收盘，诺诚健华报收于29.57元，较前一交易日上涨3.86%，最新总市值为522.52亿元。该股当日开盘28.38元，最高30.05元，最低27.06元，成交额达5.37亿元，换手率为6.89%。近日，诺诚健华医药有限公司披露公告显示，公司于2026年6月30日根据2023年股权激励计划向八名承授人授出1,910,000份受限制股份单位，占公司已发行股份总数约0.11%。1,480,000份受限制股份单位将在一至四年内分四期等额归属，其余430,000份以达成公司及个人层面业绩目标为归属条件。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100043446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1161","688428","BK1574","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648786597","title":"半导体设备板块短线走低，恒运昌跌超13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648786597","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648786597?lang=zh_cn&edition=full","pubTime":"2026-07-01 14:17","pubTimestamp":1782886664,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["688037","BK0251","688082","BK0259","688428","BK0239","09969","688409"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647832239","title":"6月29日诺诚健华涨13.08%，富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647832239","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647832239?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:39","pubTimestamp":1782722398,"startTime":"0","endTime":"0","summary":"证券之星消息，6月29日诺诚健华涨13.08%，收盘报28.61元，换手率8.5%，成交量23.01万手，成交额6.36亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共28家，其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为31.86亿元，最新净值2.9889，较上一交易日下跌3.51%，近一年下跌3.06%。富国精准医疗混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024475.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1574","09969","688428","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647223153","title":"诺诚健华涨13.08%，长城国瑞证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2647223153","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647223153?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:39","pubTimestamp":1782722392,"startTime":"0","endTime":"0","summary":"今日诺诚健华涨13.08%，收盘报28.61元。2026年3月31日，长城国瑞证券研究员胡晨曦,魏钰琪发布了对诺诚健华的研报《盈利拐点初现，商业化放量与技术授权双轮驱动》，该研报对诺诚健华给出“买入”评级。因此，我们维持其“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为国海证券的孔维崎、周小刚。诺诚健华个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024472.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688428","09969","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646840353","title":"诺诚健华(09969)：根据2024年人民币股股份激励计划发行241.83万股新人民币股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2646840353","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646840353?lang=zh_cn&edition=full","pubTime":"2026-06-26 17:16","pubTimestamp":1782465406,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华(09969)发布公告，于2026年6月26日，根据2024年人民币股股份激励计划首次授予部分第一个归属期的归属结果向2名董事发行79.5万股新人民币股份(于2024年12月17日采纳)。于2026年6月26日，根据2024年人民币股股份激励计划首次授予部分第一个归属期的归属结果向2名高级管理人员发行20万股新人民币股份(于2024年12月17日采纳)。于2026年6月26日，根据2024年人民币股股份激励计划首次授予部分第一个归属期的归属结果向70名激励对象发行142.23万股新人民币股份(于2024年12月17日采纳)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1459411.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MCNHmain","BK0239","CNHmain","CYB","BK1161","UCmain","BK1574","688428","MUCmain","09969"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1784223845356,"stockEarnings":[{"period":"1week","weight":0.0038},{"period":"1month","weight":0.2948},{"period":"3month","weight":-0.0516},{"period":"6month","weight":0.3247},{"period":"1year","weight":-0.0344},{"period":"ytd","weight":0.4235}],"compareEarnings":[{"period":"1week","weight":-0.0382},{"period":"1month","weight":-0.0512},{"period":"3month","weight":-0.0417},{"period":"6month","weight":-0.0535},{"period":"1year","weight":0.1081},{"period":"ytd","weight":-0.0218}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"诺诚健华医药有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"20000人(较上一季度增加0.00%)","perCapita":"13641股","listingDate":"2022-09-21","address":"Ogier Global (Cayman) Limited, 89 Nexus Way, Camana Bay, Grand Cayman, KY1-9009, Cayman Islands","registeredCapital":"0万元","survey":" 诺诚健华医药有限公司的主营业务是创新药的研发、生产及商业化。公司的主要产品是奥布替尼。","listedPrice":11.03},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺诚健华(688428)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺诚健华(688428)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺诚健华,688428,诺诚健华股票,诺诚健华股票老虎,诺诚健华股票老虎国际,诺诚健华行情,诺诚健华股票行情,诺诚健华股价,诺诚健华股市,诺诚健华股票价格,诺诚健华股票交易,诺诚健华股票购买,诺诚健华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺诚健华(688428)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺诚健华(688428)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}